Short Interest in First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Rises By 500.0%

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) saw a large increase in short interest in September. As of September 15th, there was short interest totaling 600 shares, an increase of 500.0% from the August 31st total of 100 shares. Based on an average trading volume of 5,700 shares, the days-to-cover ratio is currently 0.1 days. Based on an average trading volume of 5,700 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of FTXH. NBC Securities Inc. lifted its holdings in First Trust Nasdaq Pharmaceuticals ETF by 21,400.0% during the 1st quarter. NBC Securities Inc. now owns 1,075 shares of the company’s stock worth $29,000 after buying an additional 1,070 shares during the period. Cambridge Investment Research Advisors Inc. lifted its holdings in First Trust Nasdaq Pharmaceuticals ETF by 19.2% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 16,567 shares of the company’s stock worth $455,000 after buying an additional 2,663 shares during the period. Envestnet Asset Management Inc. lifted its holdings in First Trust Nasdaq Pharmaceuticals ETF by 14.6% during the 1st quarter. Envestnet Asset Management Inc. now owns 18,799 shares of the company’s stock worth $517,000 after buying an additional 2,396 shares during the period. LPL Financial LLC lifted its holdings in First Trust Nasdaq Pharmaceuticals ETF by 87.7% during the 1st quarter. LPL Financial LLC now owns 104,902 shares of the company’s stock worth $2,884,000 after buying an additional 49,026 shares during the period. Finally, OLD Mission Capital LLC acquired a new position in First Trust Nasdaq Pharmaceuticals ETF during the 1st quarter worth about $433,000.

First Trust Nasdaq Pharmaceuticals ETF Stock Down 0.6%

NASDAQ FTXH opened at $29.49 on Friday. First Trust Nasdaq Pharmaceuticals ETF has a twelve month low of $23.28 and a twelve month high of $29.76. The company has a market cap of $16.22 million, a price-to-earnings ratio of 14.51 and a beta of 0.70. The business’s fifty day moving average is $27.56 and its 200 day moving average is $26.37.

First Trust Nasdaq Pharmaceuticals ETF Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Thursday, September 25th were issued a dividend of $0.1453 per share. This represents a $0.58 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend was Thursday, September 25th. This is a boost from First Trust Nasdaq Pharmaceuticals ETF’s previous quarterly dividend of $0.09.

First Trust Nasdaq Pharmaceuticals ETF Company Profile

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.